Endothelial function as a functional expression of cardiovascular risk factors

Biomarkers in Medicine

Volumn 4, Issue 3, 2010, Pages 351-360

  Reriani, Martin K ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Atherosclerosis; Endothelial dysfunction; Endothelium; Surrogate marker; Therapeutic end point; Vascular health

Indexed keywords

ACETYLCHOLINE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTERY; ARTERY DIAMETER; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG INFUSION; EXERCISE; GOLD STANDARD; HEART MUSCLE BLOOD FLOW; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INTRACORONARY INFUSION; MICROCIRCULATION; MORTALITY; NON INVASIVE PROCEDURE; PLETHYSMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PREDICTION; RESISTANCE BLOOD VESSEL; REVIEW; RISK FACTOR; TONOMETRY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RISK FACTORS;

EID: 77953775772     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.61     Document Type: Review

References (67)

1. Wang TJ, Gona P, Larson MG et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355(25), 2631-2639 (2006).
2. Melander O, Newton-Cheh C, Almgren P et al.: Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302(1), 49-57 (2009).
3. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. hromb. Vasc. Biol. 23(2), 168-175 (2003).
4. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789), 373-376 (1980).
5. Yanagisawa M, Kurihara H, Kimura S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163), 411-415 (1988).
6. Cooke JP, Tsao PS: Is NO an endogenous antiatherogenic molecule? Arterioscler. Thromb. 14(5), 653-655 (1994).
7. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113(13), 1708-1714 (2006).
8. Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and clinical relevance. Circulation 115(10), 1285-1295 (2007).
9. Ganz P, Vita JA: Testing endothelial vasomotor function: nitric oxide, a multipotent molecule. Circulation 108(17), 2049-2053 (2003).
10. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J. Am. Coll. Cardiol. 34(3), 631-638 (1999).
11. Mathew V, Hasdai D, Lerman A: The role of endothelin in coronary atherosclerosis. Mayo Clin. Proc. 71(8), 769-777 (1996).
12. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325(14), 997-1001 (1991).
13. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92(9), 2426-2431 (1995).
14. Eitel I, Nowak M, Stehl C et al.: Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am. Heart J. 159(5), 882-890 (2010).
15. Celermajer DS: Reliable endothelial function testing: at our fingertips? Circulation 117(19), 2428-2430 (2008).
16. Hasdai D, Lerman A: The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz 24(7), 544-547 (1999).
17. Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, Schafers KP, Luscher TF, Camici PG: Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 102(11), 1233-1238 (2000).
18. Osto E, Coppolino G, Volpe M, Cosentino F: Restoring the dysfunctional endothelium. Curr. Pharm. Des. 13(10), 1053-1068 (2007).
19. Hewlett AW, Zwaluwenburg JG: The rate of blood flow in the arm. Heart 631-646 (1909).
20. Petrie JR, Ueda S, Morris AD, Murray LS, Elliott HL, Connell JM: How reproducible is bilateral forearm plethysmography? Br. J. Clin. Pharmacol. 45(2), 131-139 (1998).
21. Roberts DH, Tsao Y, Breckenridge AM: The reproducibility of limb blood flow measurements in human volunteers at rest and after exercise by using mercury-in-Silastic strain gauge plethysmography under standardized conditions. Clin. Sci. (Lond.) 70(6), 635-638 (1986).
22. Alam TA, Seifalian AM, Baker D: A review of methods currently used for assessment of in vivo endothelial function. Eur. J. Vasc. Endovasc. Surg. 29(3), 269-276 (2005).
23. Anderson TJ, Uehata A, Gerhard MD et al.: Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26(5), 1235-1241 (1995).
24. Deanfield J, Donald A, Ferri C et al.: Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 23(1), 7-17 (2005). (Pubitemid 40128972)
25. Joannides R, Haefeli WE, Linder L et al.: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91(5), 1314-1319 (1995).
26. Celermajer DS, Sorensen KE, Gooch VM et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340(8828), 1111-1115 (1992).
27. Bonetti PO, Barsness GW, Keelan PC et al.: Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J. Am. Coll. Cardiol. 41(10), 1761-1768 (2003).
28. Krantz DS, Santiago HT, Kop WJ, Bairey Merz CN, Rozanski A, Gottdiener JS: Prognostic value of mental stress testing in coronary artery disease. Am. J. Cardiol. 84(11), 1292-1297 (1999).
29. Lavie P, Shlitner A, Sheffy J, Schnall RP: Peripheral arterial tonometry: a novel and sensitive non-invasive monitor of brief arousals during sleep. Isr. Med. Assoc. J. 2(3), 246-247 (2000).
30. Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A: Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol. 44(11), 2137-2141 (2004).
31. Hamburg NM, Keyes MJ, Larson MG et al.: Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 117(19), 2467-2474 (2008).
32. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A: Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 107(22), 2805-2809 (2003).
33. Kuvin JT, Patel AR, Sliney KA et al.: Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am. Heart J. 146(1), 168-174 (2003).
34. Rubinshtein R, Kuvin JT, Soffler M et al.: Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur. Heart J. 31(9), 1142-1148 (2010).
35. Patvardhan EA, Heffernan KS, Ruan JM, Soffler MI, Karas RH, Kuvin JT: Assessment of vascular endothelial function with peripheral arterial tonometry: information at your fingertips? Cardiol. Rev. 18(1), 20-28 (2010).
36. Kuvin JT, Mammen A, Mooney P, Alsheikh-Ali AA, Karas RH: Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc. Med. 12(1), 13-16 (2007).
37. Brunner H, Cockcroft JR, Deanfield J et al.: Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 23(2), 233-246 (2005). (Pubitemid 40279622)
38. Braunwald E: Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337(19), 1360-1369 (1997).
39. Brindle P, Emberson J, Lampe F et al.: Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327(7426), 1267 (2003).
40. Wong J, Wong V, Fahey T, Brindle P, Hay A: Predictors of postmenopausal osteoporosis: study methods and analysis require clarification. BMJ 327(7411), 392; author reply 392-393 (2003).
41. Menotti A, Keys A, Aravanis C et al.: Seven Countries Study. First 20-year mortality data in 12 cohorts of six countries. Ann. Med. 21(3), 175-179 (1989).
42. Kinlay S, Ganz P: Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am. J. Cardiol. 80(9A), 11I-16I (1997). (Pubitemid 27490822)
43. Naghavi M, Libby P, Falk E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108(15), 1772-1778 (2003). (Pubitemid 37296082)
44. Naghavi M, Libby P, Falk E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108(14), 1664-1672 (2003). (Pubitemid 37243650)
45. Matsuzawa Y, Sugiyama S, Sugamura K et al.: Digital assessment of endothelial function and ischemic heart disease in women. J. Am. Coll. Cardiol. 55(16), 1688-1696 (2010).
46. Sugiyama S, Sugamura K, Nozaki T et al.: Endothelial function and ischemic heart disease in women. J. Am. Coll. Cardiol. 55(16), 1688-1696 (2010).
47. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104(3), 365-372 (2001).
48. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 105(9), 1135-1143 (2002).
49. Lavi S, Yang EH, Prasad A et al.: The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 51(1), 127-133 (2008).
50. McGorisk GM, Treasure CB: Endothelial dysfunction in coronary heart disease. Curr. Opin. Cardiol. 11(4), 341-350 (1996).
51. Golino P, Piscione F, Willerson JT et al.: Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324(10), 641-648 (1991).
52. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA: The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 42(7), 1149-1160 (2003).
53. Lerman A, Zeiher AM: Endothelial function: cardiac events. Circulation 111(3), 363-368 (2005).
54. Kitta Y, Obata JE, Nakamura T et al.: Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J. Am. Coll. Cardiol. 53(4), 323-330 (2009).
55. Tantikosoom W, Thinkhamrop B, Kiatchusakul S, Jarernsiripornkul N, Srinakarin J, Ojongpian S: Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level. J. Med. Assoc. hai. 88(3), 399-406 (2005).
56. Treasure CB, Klein JL, Weintraub WS et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332(8), 481-487 (1995).
57. Van Venrooij FV, Van De Ree MA, Bots ML, Stolk RP, Huisman MV, Banga JD: Aggressive lipid lowering does not improve endothelial function in Type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25(7), 1211-1216 (2002).
58. Vita JA, Yeung AC, Winniford M et al.: Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102(8), 846-851 (2000).
59. Wassmann S, Ribaudo N, Faul A, Laufs U, Bohm M, Nickenig G: Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. Am. J. Cardiol. 93(1), 84-88 (2004).
60. Ridker PM, Danielson E, Fonseca FA et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
61. McRae MP: High-dose folic acid supplementation effects on endothelial function and blood pressure in hypertensive patients: a meta-analysis of randomized controlled clinical trials. J. Chiropr. Med. 8(1), 15-24 (2009).
62. Balk EM, Karas RH, Jordan HS, Kupelnick B, Chew P, Lau J: Effects of statins on vascular structure and function: a systematic review. Am. J. Med. 117(10), 775-790 (2004).
63. Hambrecht R, Wolf A, Gielen S et al.: Effect of exercise on coronary endothelial function in patients with coronary artery disease. N. Engl. J. Med. 342(7), 454-460 (2000).
64. Raghuraj P, Telles S: Immediate effect of specific nostril manipulating yoga breathing practices on autonomic and respiratory variables. Appl. Psychophysiol. Biofeedback 33(2), 65-75 (2008).
65. Blumenthal JA, Sherwood A, Babyak MA et al.: Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease: a randomized controlled trial. JAMA 293(13), 1626-1634 (2005).
66. Paul-Labrador M, Polk D, Dwyer JH et al.: Effects of a randomized controlled trial of transcendental meditation on components of the metabolic syndrome in subjects with coronary heart disease. Arch. Intern. Med. 166(11), 1218-1224 (2006).
67. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R: Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J. Am. Coll. Cardiol. 40(3), 505-510 (2002).